Pay in 4 interest-free payments of $5.41 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
Why is BPC-157 sold as research use only
Can BPC-157 be combined with psychiatric medications
Free from unnecessary additives, gluten, lactose, soy and GMOs
Tirzepatide Dual agonist : GLP-1 + GIP Central benchmark for dual incretin research Often discussed in relation to body-weight outcomes, glycaemic control and incretin signalling Single agonist : GLP-1 More selective and mechanistically narrower Common reference point for GLP-1 pathway research Triple agonist : GLP-1 + GIP + glucagon Broader receptor profile than Tirzepatide Often discussed in relation to weight loss, energy expenditure and next-generation multi-pathway metabolic modulation For researchers comparing incretin classes, Tirzepatide often functions as the middle reference point between single-pathway GLP-1 agonists and broader triple-agonist designs
/assets/images/provider/photos/2813769.png)
